Expression of ALCAM/CD166 in Breast Infiltrative Ductal Cancer Tissues and Its Relation with Bcl-2 or Ki-67_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LINBing-huang ¹ ,  HUANGRong-jin ¹ , HEQing-an ¹ , LIYan-fang ¹ , WANGJin-sheng ¹ , YANGYi-hong ² , HONGChao-hui ¹

1. Department of General Surgery, Affiliated People's Hospital of Quanzhou Medical College, Quanzhou 362000, Fujian Province, China;
2. Department of Pathology, Affiliated People's Hospital of Quanzhou Medical College, Quanzhou 362000, Fujian Province, China;

Corresponding author：

HUANGRong-jin, Email: hrongjin2008@126.com

Keywords：

Breast tumor; ALCAM/CD16; Bcl-2; Ki-67; Immunohistochemistry

DOI：

10.7507/1007-9424.20150383

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate expressions of ALCAM/CD166, Bcl-2, and Ki-67 in breast infiltrative ductal cancer tissues, so as to assess the role of ALCAM/CD166 protein in the carcinogenesis and progression of breast infiltrative ductal cancer. Methods The expressions of ALCAM/CD166, Bcl-2, and Ki-67 proteins were examined by immunohistochemistry(Elivision^TM Plus) in 96 breast infiltrative ductal cancer specimens and 30 adjacent normal tissues of breast cancer specimens(control group). The relation between ALCAM/CD166 protein expression and patient's age, tumor diameter, histopathologic grade, axillary lymph node metastasis, or TNM stage of breast infiltrative ductal cancer was analyzed, and the correlation between ALCAM/CD166 expression and Bcl-2 or Ki-67 was analyzed too. Results ①In 96 cases of breast infiltrative ductal cancer, the positive rate of ALCAM/CD166 protein expression was 79.2%(76/96), which was significantly higher than that in the control group〔10.0%(3/30), P < 0.01〕.②In the breast infiltrative ductal cancer tissues, the expression of ALCAM/CD166 was related to axillary lymph node metastasis(P < 0.05), but was not related to patient's age, tumor diameter, histopathologic grade, and TNM stage(P > 0.05).③The ALCAM/CD166 protein expression was positively related to Bcl-2(r_s=0.307, P=0.001) and not related to Ki-67(r_s=0.064, P=0.475). Conclusion ALCAM/CD166 protein expression might be related to the apoptosis and metastasis of breast infiltrative ductal cancer cells and it could serve as an important marker for predicting biological behavior and prognosis of tumor.

Citation： LINBing-huang, HUANGRong-jin, HEQing-an, LIYan-fang, WANGJin-sheng, YANGYi-hong, HONGChao-hui. Expression of ALCAM/CD166 in Breast Infiltrative Ductal Cancer Tissues and Its Relation with Bcl-2 or Ki-67. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(12): 1466-1470. doi: 10.7507/1007-9424.20150383 Copy

1.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
2.	Degen WG, Van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM(activated leukocyte cell adhesion molecule). Am J Pathol, 1998, 152(3): 805-813.
3.	Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins, 2000, 40(3): 420-428.
4.	Ohneda O, Ohneda K, Arai F, et al. ALCAM(CD166): its role in hematopoietic and endothelial development. Blood, 2001, 98(7): 2134-2142.
5.	Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let, s do it. Am J Clin Pathol, 1995, 103(2): 123-124.
6.	Hein S, Müller V, Köhler N, et al. Biologic role of activated leuko-cyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat, 2011, 129(2): 347-360.
7.	Van Kempen LC, Van Den Oord JJ, Van Muijen GN, et al. Activa-ted leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol, 2000, 156(3): 769-774.
8.	Hassan NJ, Barclay AN, Brown MH. Frontline: optimal T cell activa-tion requires the engagement of CD6 and CD166. Eur J Immunol, 2004, 34(4): 930-940.
9.	Zimmerman AW, Joosten B, Torensma R, et al. Long-term engage-ment of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood, 2006, 107(8): 3212-3220.
10.	Van Kempen LC, Meier F, Egeblad M, et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol, 2004, 122(5): 1293-1301.
11.	Weichert W, Knösel T, Bellach J, et al. ALCAM/CD166 is overex-pressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol, 2004, 57(11): 1160-1164.
12.	Fujiwara K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activi-ties of pancreatic cancer cells. PLoS One, 2014, 9(9): e107247.
13.	Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol, 2005, 205(3): 359-376.
14.	Burkhardt M, Mayordomo E, Winzer KJ, et al. Cytoplasmic overex-pression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol, 2006, 59(4): 403-409.
15.	Piao D, Jiang T, Liu G, et al. Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer. Mol Biol Rep, 2012, 39(1): 661-668.
16.	王斌斌, 刘彩刚, 张昊, 等.活化白细胞黏附分子(ALCAM)在乳腺癌的表达及其临床意义.中国肿瘤临床, 2011, 38(18): 1139-1144.
17.	King JA, Ofori-Acquah SF, Stevens T, et al. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res, 2004, 6(5): R478-R487.
18.	Jezierska A, Olszewski WP, Pietruszkiewicz J, et al. Activated leukocyte cell adhesion molecule(ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit, 2006, 12(7): BR245-BR256.
19.	Davies S, Jiang WG. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive Nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res, 2010, 30(4): 1163-1168.
20.	Lunter PC, Van Kilsdonk JW, Van Beek H, et al. Activated leukocyte cell adhesion molecule(ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res, 2005, 65(19): 8801-8808.
21.	Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit, 2006, 12(8): BR263-BR273.

1. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
2. Degen WG, Van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM(activated leukocyte cell adhesion molecule). Am J Pathol, 1998, 152(3): 805-813.
3. Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins, 2000, 40(3): 420-428.
4. Ohneda O, Ohneda K, Arai F, et al. ALCAM(CD166): its role in hematopoietic and endothelial development. Blood, 2001, 98(7): 2134-2142.
5. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let, s do it. Am J Clin Pathol, 1995, 103(2): 123-124.
6. Hein S, Müller V, Köhler N, et al. Biologic role of activated leuko-cyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat, 2011, 129(2): 347-360.
7. Van Kempen LC, Van Den Oord JJ, Van Muijen GN, et al. Activa-ted leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol, 2000, 156(3): 769-774.
8. Hassan NJ, Barclay AN, Brown MH. Frontline: optimal T cell activa-tion requires the engagement of CD6 and CD166. Eur J Immunol, 2004, 34(4): 930-940.
9. Zimmerman AW, Joosten B, Torensma R, et al. Long-term engage-ment of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood, 2006, 107(8): 3212-3220.
10. Van Kempen LC, Meier F, Egeblad M, et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol, 2004, 122(5): 1293-1301.
11. Weichert W, Knösel T, Bellach J, et al. ALCAM/CD166 is overex-pressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol, 2004, 57(11): 1160-1164.
12. Fujiwara K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activi-ties of pancreatic cancer cells. PLoS One, 2014, 9(9): e107247.
13. Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol, 2005, 205(3): 359-376.
14. Burkhardt M, Mayordomo E, Winzer KJ, et al. Cytoplasmic overex-pression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol, 2006, 59(4): 403-409.
15. Piao D, Jiang T, Liu G, et al. Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer. Mol Biol Rep, 2012, 39(1): 661-668.
16. 王斌斌, 刘彩刚, 张昊, 等.活化白细胞黏附分子(ALCAM)在乳腺癌的表达及其临床意义.中国肿瘤临床, 2011, 38(18): 1139-1144.
17. King JA, Ofori-Acquah SF, Stevens T, et al. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res, 2004, 6(5): R478-R487.
18. Jezierska A, Olszewski WP, Pietruszkiewicz J, et al. Activated leukocyte cell adhesion molecule(ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit, 2006, 12(7): BR245-BR256.
19. Davies S, Jiang WG. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive Nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res, 2010, 30(4): 1163-1168.
20. Lunter PC, Van Kilsdonk JW, Van Beek H, et al. Activated leukocyte cell adhesion molecule(ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res, 2005, 65(19): 8801-8808.
21. Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit, 2006, 12(8): BR263-BR273.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of ALCAM/CD166 in Breast Infiltrative Ductal Cancer Tissues and Its Relation with Bcl-2 or Ki-67

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content